Researchers at Vanderbilt University have worked out part of the “wiring diagram” of a signaling system in the brain that has been linked to autism spectrum disorder (ASD).
Their findings, published in January in the journal Biological Psychiatry, raise hopes for a new approach to treating ASD, which affects an estimated 1 in every 68 children in the United States.
The focus of the study was the endocannabinoid system, which also is associated with mood, anxiety, and stress disorders. Endocannabinoids are lipid molecules made by neurons that activate the same receptor as the active ingredients of marijuana.
Decision-making, motivation, and reinforcement of reward are all coordinated by the striatum, the part of the brain that controls voluntary behavior, said senior author Brian Shonesy, Ph.D., research instructor in the Department of Molecular Physiology & Biophysics.
The striatum has two neural pathways: the direct pathway, which acts like an automobile “accelerator” and facilitates behavior; and the indirect pathway, akin to the “brake,” which suppresses unwanted behavior. Neurons projecting from sensory, emotional, and cognitive areas of the brain interact with these pathways to modulate these behaviors.
Across the brain, endocannabinoids can be released by neurons to dampen the level of activation they receive from other neurons. In this way, they act like a dimmer switch to allow precise control of neuron circuits.
The most abundant endocannabinoid is 2-arachidonoylglycerol (2-AG), which is synthesized by the enzyme diacylglycerol lipase alpha (DGL alpha).
Using a conditional knockout mouse model, Shonesy and his colleagues deleted the gene for DGL alpha from neurons in either the direct or indirect pathway to study how endocannabinoids may control the flow of information through the striatum.
Targeted deletion of the enzyme from direct but not indirect pathway neurons caused deficits in social interaction and excessive grooming. These are the mouse “equivalents” of two cardinal characteristics of ASD in humans, said co-author Roger Colbran, Ph.D., professor of Molecular Physiology & Biophysics and acting chair of the department, and Vanderbilt Kennedy Center investigator.
These results suggest that endocannabinoid dysfunction may result in an imbalance between the “accelerator” and “brake” pathways, leading to abnormal behaviors.
Additional findings from the study suggest that social interaction deficits resulting from endocannabinoid deficiency may arise from the back or dorsal parts of the striatum, whereas repetitive behaviors may emerge from the front or ventral striatum.
Deficits in 2-AG signaling have been linked to ASD in humans. While the Vanderbilt findings reflect the complexity of striatal circuitry, the researchers suggested that manipulation of endocannabinoid signaling one day may represent a useful therapeutic tool.
Also contributing to the study were Danny Winder, Ph.D., director of the Vanderbilt Center for Addiction Research and VKC investigator; Sachin Patel, M.D., Ph.D., associate professor of Psychiatry & Behavioral Sciences and VKC member; and their labs. The study was supported in part by National Institutes of Health grants MH107765, MH106192, NS078291, DA021696, and AA000416.
Bill Snyder is senior science writer, VUMC News and Communications. This article is republished from Research News @ Vanderbilt, Feb. 8, 2018.